X

Starte jetzt beim Kostensieger der Stiftung Warentest (12/2025)

Aktiendepot mit Profi-Funktionen, kostenlose ETF-Sparpläne, Krypto-Wallet mit echten Coins, Derivate von 6 Top-Emittenten: Unser Broker vereint all das auf einer modernen Plattform. Eröffne jetzt dein kostenloses Depot bei finanzen.net ZERO!

Jetzt kostenlos starten …oder hier informieren

Nicht mehr anzeigen

Medincell Aktie

Kaufen

Verkaufen

Medincell Aktien-Sparplan Medincell Aktien-Sparplan

27,70 EUR +0,08 EUR +0,29 %

15:31:10

STU

25,14 CHF -0,37 CHF -1,45 %

15:55:54

BRX

Medincell jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Smartphone

Marktkap.1,03 Mrd. EUR

Div. Rendite0,00%

WKNA2N6VA

ISINFR0004065605

SymbolMDCLF

Medincell Aktien News

Sortieren:Datum Meistgelesen

12.12.24BusinesswireMedincell to Join the Euronext SBF 120 Index

09.12.24BusinesswireMedincell and AIC Unveil New Positive Phase 3 Results for mdc-CWM: Major Subgroup Analysis Shows Reduced Pain and Opioid Use, and Accelerated Rehabilitation following Total Knee Replacement

06.11.24BusinesswireMedincell: 25% Raise in 2024 UZEDY® Revenue Outlook & Key Milestone Reached for Olanzapine LAI Clinical Phase 3

WerbungMedincell-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

04.11.24BusinesswireMedincell’s Partner Teva Unveils New Phase 3 Positive Results for Olanzapine LAI, and Presents Real-World Data on UZEDY® at Psych Congress 20241

23.09.24BusinesswireMedincell’s Partner Teva Presented New Efficacy, Safety, and Tolerability Data from Pivotal Phase 3 of Olanzapine LAI for Adult Patients Diagnosed with Schizophrenia

23.09.24BusinesswireMedincell’s Partner Teva Provided Treatment Insights into Switching to UZEDY® from Perseris®

05.09.24BusinesswireMedincell’s Partner Teva Provides New Update on Pivotal Clinical Phase 3 of Investigational Olanzapine Long-Acting Injectable (LAI)

03.09.24BusinesswireMedincell Announces Progress in the Development of its Products Portfolio and R&D Pipeline

31.07.24BusinesswireMedincell’s partner Teva provides update on pivotal clinical Phase 3 of investigational Olanzapine Long-Acting Injectable (LAI) and UZEDY® commercial progress

08.05.24BusinesswireTeva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia

16.04.24BusinesswireMedincell Enters Into Strategic Co-development and Licensing Agreement with AbbVie to Develop Next-generation Long-acting Injectable Therapies

08.04.24BusinesswireUnitaid Awards Medincell up to $6 million Extension Grant to Fight Malaria

31.01.24BusinesswireMedinCell’s Partner Teva Provides Guidance for UZEDY in 2024 and an Update on the Treatment-Candidate of Olanzapine Long-Acting Injectable (LAI)

09.01.24BusinesswireMedinCell’s partner Teva Announces Recruitment Completion of Phase 3 Clinical Study of mdc-TJK / Olanzapine Long-Acting Injectable (LAI)

13.11.23BusinesswireMedinCell Applauds Teva and Royalty Pharma Collaboration to Further Accelerate Olanzapine LAI Program (Codename: mdc-TJK or TEV-‘749)

30.08.23BusinesswireMedinCell announces successful completion of patient enrollment in the Phase 3 study of F14 (mdc-CWM), a first-in-class therapy for localized pain relief after Total Knee Replacement

Medincell News

Medincell News: auf dieser Seite finden Sie alle Medincell News und Nachrichten zur Medincell Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Medincell News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Medincell News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.